Our group has previously linked mutations in TP53, (in particular those affecting the L2/L3 DNA binding domains), to resistance to anthracyclines and the related cytotoxic compound, mitomycin, in primary breast cancers [8-10]. The gene discussed is TP53; the disease is breast carcinoma.